{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C&page=2",
    "query": {
      "condition": "Hepatitis C",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T15:03:39.232Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03146741",
      "title": "Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Zepatier",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2017-05-16",
      "completion_date": "2019-11-30",
      "has_results": true,
      "last_update_posted_date": "2021-11-22",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03146741"
    },
    {
      "nct_id": "NCT01309932",
      "title": "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Pegylated Interferon Lambda (pegIFNλ)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BMS-790052 (NS5A Inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (RBV)",
          "type": "DRUG"
        },
        {
          "name": "BMS-650032 (NS3 Protease Inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon Alfa-2a (pegIFNα-2a)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Ribavirin (RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 165,
      "start_date": "2011-03",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2015-10-09",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01309932"
    },
    {
      "nct_id": "NCT01359644",
      "title": "Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "PSI-7977",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 350,
      "start_date": "2011-06",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2015-10-23",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 17,
      "location_summary": "Coronado, California • San Diego, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01359644"
    },
    {
      "nct_id": "NCT01206933",
      "title": "The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Immunodeficiency Virus (HIV)",
        "Hepatitis C, Chronic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "George Washington University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-07",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-02-10",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01206933"
    },
    {
      "nct_id": "NCT03898349",
      "title": "eHealth Partnered Evaluation Initiative - Evaluation of the Initial Deployment of VA's Annie Texting System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Annie text messaging system",
          "type": "OTHER"
        },
        {
          "name": "Annie text messaging system with Usual implementation",
          "type": "OTHER"
        },
        {
          "name": "Annie text messaging system with Augmented implementation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 750,
      "start_date": "2015-10-01",
      "completion_date": "2017-09-30",
      "has_results": true,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 1,
      "location_summary": "Bedford, Massachusetts",
      "locations": [
        {
          "city": "Bedford",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03898349"
    },
    {
      "nct_id": "NCT04513899",
      "title": "Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C Virus (HCV) Infection"
      ],
      "interventions": [
        {
          "name": "Community health worker (CHW)/ registered nurse (RN) [CHW/RN]",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinic-based Standard of Care (cbSOC) Program (control group)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-10-05",
      "completion_date": "2022-07-20",
      "has_results": true,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04513899"
    },
    {
      "nct_id": "NCT01579162",
      "title": "Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C, Chronic",
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "HepQuant, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "22 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2012-01",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579162"
    },
    {
      "nct_id": "NCT02772003",
      "title": "DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis",
        "Hepatitis C Infection",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Electroporation-Mediated Plasmid DNA Vaccine Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HCV DNA Vaccine INO-8000",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Rocakinogene Sifuplasmid",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2016-06-06",
      "completion_date": "2027-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Rochester, Minnesota • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02772003"
    },
    {
      "nct_id": "NCT01899092",
      "title": "Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "TT-034",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tacere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2014-01",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2016-11-30",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Durham, North Carolina • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01899092"
    },
    {
      "nct_id": "NCT03823911",
      "title": "Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Hepatitis C",
        "Hiv"
      ],
      "interventions": [
        {
          "name": "Elbasvir / Grazoprevir Oral Tablet [Zepatier]",
          "type": "DRUG"
        },
        {
          "name": "Cardiac MRI",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 87,
      "start_date": "2018-11-18",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-05-22",
      "last_synced_at": "2026-06-07T15:03:39.232Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03823911"
    }
  ]
}